(-0.34%) 5 018.39 points
(0.23%) 37 903 points
(-0.33%) 15 605 points
(0.73%) $79.58
(1.24%) $1.956
(0.75%) $2 328.40
(0.31%) $26.83
(1.36%) $967.90
(0.00%) $0.933
(-0.10%) $11.02
(-0.09%) $0.798
(-0.26%) $93.02
Live Chart Being Loaded With Signals
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics...
Stats | |
---|---|
今日成交量 | 4 200.00 |
平均成交量 | 203 956 |
市值 | 2.04B |
EPS | HKD0 ( 2024-03-25 ) |
Last Dividend | HKD0 ( N/A ) |
Next Dividend | HKD0 ( N/A ) |
P/E | -7.31 |
ATR14 | HKD0 (0.00%) |
SinoMab BioScience Ltd 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
SinoMab BioScience Ltd 财务报表
Annual | 2023 |
营收: | HKD4.39M |
毛利润: | HKD3.45M (78.53 %) |
EPS: | HKD-0.240 |
FY | 2023 |
营收: | HKD4.39M |
毛利润: | HKD3.45M (78.53 %) |
EPS: | HKD-0.240 |
FY | 2022 |
营收: | HKD4.03M |
毛利润: | HKD4.03M (100.00 %) |
EPS: | HKD-0.290 |
FY | 2021 |
营收: | HKD25.91M |
毛利润: | HKD0.00 (0.00 %) |
EPS: | HKD-0.286 |
Financial Reports:
No articles found.
SinoMab BioScience Ltd
SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics. Its flagship product is SM03, a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA), as well as in various clinical stages for other immunological diseases, such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SS), and non-Hodgkin's lymphoma (NHL). The company also focuses on developing SN1011, a Bruton's tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, as well as in phase 1 clinical trial to treat multiple sclerosis, SLE, and NMOSD. Its products under the preclinical stage comprise SM17 for the treatment of asthma, atopic dermatitis, and idiopathic pulmonary fibrosis; SM06 to treat RA, SLE, NMOSD, and SS; SM09 for the treatment of NHL and RA; and TNF2 for the treatment of autoimmune diseases. The company operates in Mainland China, the Cayman Islands, and Hong Kong. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Pak Shek Kok, Hong Kong.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。